Femoston-conti 1mg/ 5mg film-coated tablets
Last Updated on eMC 30-Aug-2016 View document | Mylan Products Limited Contact details
Versions
- 30-Aug-2016 to Current
- 11-May-2016 to 30-Aug-2016
- 28-Apr-2015 to 11-May-2016
- 26-Mar-2015 to 28-Apr-2015
- 28-Jul-2014 to 26-Mar-2015
- 03-Jan-2013 to 28-Jul-2014
- 11-Oct-2012 to 03-Jan-2013
- 08-May-2012 to 11-Oct-2012
- 14-Jun-2010 to 08-May-2012
- 17-Sep-2008 to 14-Jun-2010
- 25-Oct-2006 to 17-Sep-2008
- 23-Apr-2004 to 25-Oct-2006
- 04-Jul-2001 to 23-Apr-2004
When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.
Updated on 30-Aug-2016 and displayed until Current
Reasons for adding or updating:
- Change to section 6 - marketing authorisation holder
Updated on 11-May-2016 and displayed until 30-Aug-2016
Reasons for adding or updating:
- Change to section 2 - what you need to know - warnings and precautions
Updated on 28-Apr-2015 and displayed until 11-May-2016
Reasons for adding or updating:
- Change to section 6 - marketing authorisation holder
- Change to section 6 - date of revision
- Company name change or merger
Updated on 26-Mar-2015 and displayed until 28-Apr-2015
Reasons for adding or updating:
- Change to section 2 - what you need to know - contraindications
- Change to section 2 - use in children/adolescents
- Change to section 2 - interactions with other medicines, food or drink
- Change to section 2 - pregnancy, breast feeding and fertility
- Change to section 3 - overdose, missed or forgotten doses
- Change to section 4 - possible side effects
Updated on 28-Jul-2014 and displayed until 26-Mar-2015
Reasons for adding or updating:
- Change to section 6 - marketing authorisation holder
- Change to section 6 - date of revision
Updated on 03-Jan-2013 and displayed until 28-Jul-2014
Reasons for adding or updating:
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
Updated on 11-Oct-2012 and displayed until 03-Jan-2013
Reasons for adding or updating:
- Change to date of revision
- Change to warnings or special precautions for use
- Change of contra-indications
- Change to storage instructions
- Change to side-effects
- Change to drug interactions
- Change to dosage and administration
- Change due to user-testing of patient information
Updated on 08-May-2012 and displayed until 11-Oct-2012
Reasons for adding or updating:
- Change to appearance of the medicine
Updated on 14-Jun-2010 and displayed until 08-May-2012
Reasons for adding or updating:
- Change to storage instructions
- Company name change or merger
- Change to name of manufacturer
Updated on 17-Sep-2008 and displayed until 14-Jun-2010
Reasons for adding or updating:
- Transfer to upgraded management system
Updated on 25-Oct-2006 and displayed until 17-Sep-2008
Reasons for adding or updating:
- Improved Electronic Presentation
Updated on 23-Apr-2004 and displayed until 25-Oct-2006
Reasons for adding or updating:
- Change to, or new, use for medicine
- Change to warnings or special precautions for use
- Change of contra-indications
- Change to instructions about overdose
- Change to side-effects
- Change to drug interactions
- Change to date of revision
- Change to how to administer the medicine
Updated on 04-Jul-2001 and displayed until 23-Apr-2004
Reasons for adding or updating:
- Update to PIL
Mylan Products Limited
20 Station Close, Potters Bar, Hertfordshire, EN6 1TL, UK
+44 (0)1707 853000
Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?
Active ingredients
Legal categories
This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Continue